Connect with us


Nina Capital Opens a New Investment Vehicle of 50 Million

Nina Capital registers a third financing vehicle with fifty million euros, focusing on investments between 200,000 and two million euros in series A and early phases. The fund aims for twenty to thirty operations and has become a venture capital leader in digital health and medical technologies, raising over 300 million euros in five years. Notable investments include Elypta, and Magentiq Eye.



Nina Capital

Nina Capital has registered a third financing vehicle. This has been communicated to the National Securities Market Commission (Cnmv) by Marta Gaia Zanchi’s venture capital fund. According to the request, this instrument will have fifty million euros, 16% more than the previous one, about 42 million .

Nina Capital indicates in the documentation sent to the Cnmv that the objective of the new fund is the investment of sums of between 200,000 and two million euros in series A and early phases . The management company expects to carry out between twenty and thirty operations like this.

In five years, Nina Capital has positioned itself as an international benchmark in the venture capital sector in areas such as digital health and medical technologies. The manager achieved a 70% repetition rate with its previous vehicle and has invested around sixty million euros in almost fifty companies in initial stages in the last five years.

Read more about Nina Capital and find the latest financial news of the day with the Born2Invest mobile app. Our companion app is available for free for both Android and iOS devices.

Nina Capital has raised more than 300 million euros in five years

Zanchi is at the head of this venture capital fund after his time at the American Sanford University. His commitment is to invest in start-ups in pre-seed or seed capital phases in the health field. Since its creation and together with its partner Marc Subirats, they have raised more than 300 million euros .

Among its successes is the sale in 2022 to the American multinational of healthcare analysis Aetion of one of the companies in which Nina Capital invested, Replica Analytics.

Currently, among the most profitable investments of the Zanchi manager are the biotechnology company Elypta, the technology company specialized in colonoscopy Magentiq Eye, the clinical trial simulator using artificial intelligence Quanthealth, the software company aimed at data management Quantivly and the of medical image data Segmed, the medical image in radiology SubtleMedical and the technological area of ​​echocardiology Ultromics.


(Featured image by moerschy via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.